TY - JOUR
T1 - Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction—1-year follow-up results of the COMPARE CRUSH trial
AU - Vogel, Rosanne F.
AU - Wilschut, Jeroen M.
AU - Lemmert, Miguel E.
AU - Diletti, Roberto
AU - van Vliet, Ria
AU - van der Waarden, Nancy W. P. L.
AU - Nuis, Rutger-Jan
AU - Paradies, Valeria
AU - Alexopoulos, Dimitrios
AU - Zijlstra, Felix
AU - Montalescot, Gilles
AU - Angiolillo, Dominick J.
AU - Krucoff, Mitchell W.
AU - Smits, Pieter C.
AU - van Mieghem, Nicolas M.
AU - Vlachojannis, Georgios J.
N1 - Funding Information: The COMPARE CRUSH trial was funded by grants from MicroPort and Daiichi-Sankyo. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents. Funding Information: The COMPARE CRUSH trial was funded by Maasstad research B.V. (Rotterdam, the Netherlands), which received unrestricted grants from Daiichi-Sankyo (grant number 039-20170327-EFI ) and Shanghai MicroPort Medical (grant number MPSH20170801148570110945). The funding companies were not involved in the conduct of the trial, the analysis of the data, or the drafts of the manuscripts. Publisher Copyright: © 2022 Elsevier Inc.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - The present research letter reports the 1-year clinical outcomes of the randomized COMPARE CRUSH trial, which allocated STEMI patients at first medical contact in the ambulance to receive either crushed or integral tablets of prasugrel loading dose. This trial aimed to investigate whether early enhanced antiplatelet effect constituted by the crushed potent oral P2Y12 inhibitor prasugrel could lead to improved early myocardial reperfusion and clinical outcomes.
AB - The present research letter reports the 1-year clinical outcomes of the randomized COMPARE CRUSH trial, which allocated STEMI patients at first medical contact in the ambulance to receive either crushed or integral tablets of prasugrel loading dose. This trial aimed to investigate whether early enhanced antiplatelet effect constituted by the crushed potent oral P2Y12 inhibitor prasugrel could lead to improved early myocardial reperfusion and clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85133279694&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ahj.2022.05.022
DO - https://doi.org/10.1016/j.ahj.2022.05.022
M3 - Comment/Letter to the editor
C2 - 35671829
SN - 0002-8703
VL - 252
SP - 26
EP - 30
JO - American Heart Journal
JF - American Heart Journal
ER -